LXI 15029

Drug Profile

LXI 15029

Alternative Names: LXI15029; SCC-31

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chinese Academy of Sciences; Fudan University; Shandong Luoxin Pharmaceutical; Shanghai Institute of Materia Medica
  • Developer Chinese Academy of Sciences; Shandong Luoxin Pharmaceutical; Shanghai Institute of Materia Medica
  • Class Antineoplastics
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 12 Jun 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT03125746)
  • 12 Jun 2017 Phase-I clinical trials in Breast cancer (Monotherapy, Late-stage disease, Metastatic disease) in China (PO) (NCT03125746)
  • 04 May 2017 Shandong Luoxin Pharmaceutical plans a phase I trial for Breast cancer (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease) (NCT03125746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top